Raising the Bar: Abilify Maintena’s New Dosing Option and the Real-World Cost of Missed Opportunities

Rethinking ADHD Treatment: The Promise of Evening-Dosed Medication

Attention-Deficit/Hyperactivity Disorder (ADHD) affects millions of children, adolescents, and adults across the country. While symptoms like distractibility, impulsivity, and hyperactivity often take center stage, what’s less often talked about is the day-to-day disruption ADHD can cause—for both individuals and their families.

Will Antidepressants Change My Personality?

A common concern people have before starting antidepressants is: “Will this medication change who I am?” It’s a valid question—after all, your personality is what makes you unique.

The Rise of Osavampator: A New Contender in Adjunctive Depression Treatment

In a crowded market of SSRIs, SNRIs, and antipsychotic adjuncts, Osavampator represents a truly novel direction. Its efficacy is among the strongest seen in recent trials, its safety profile is remarkably clean, and its mechanism of action provides an opportunity to break from the limitations of monoamine-based therapy.

Amisulpride: The Antipsychotic Americans Can’t Have (But Maybe Should)

Amisulpride is a second-generation antipsychotic that’s been used for decades abroad for the treatment of schizophrenia and, at lower doses, persistent dysthymia.

Breaking Barriers: Optimizing the Use of Long-Acting Injectables in Psychiatry

This article highlights how long-acting injectables are essential for stability in real-world psychiatry, yet remain underutilized due to systemic, insurance, and logistical obstacles that fail to reflect the clinical realities of severe mental illness.